LIST OF TABLES

Table. 2.1	Distribution of cancer incidence and deaths for 2000	11
Table 2.2	Classification of liposomes	
	a) Based on structural parameters (size and number of bilayers)	18
	b) Based on method of liposome preparation	19
Table 2.3	Liposome-based products developed or under development	36
Table 2.4	Chromatographic techniques for determination of methotrexate	90
Table 2.5	Chromatographic techniques for determination of tamoxifen citrate	100
Table 2.6	Chromatographic techniques for determination of Cytarabine	111
Table 3.1	Calibration curve for estimation of phosphatidyl choline (Stewart assay)	118
Table 3.2	Optical characteristics for ammonium ferrothiocyanate-phosphatidyl choline complex in chloroform	118
Table 3.3	Calibration curve for estimation of cholesterol (Zlatkis, Zak and Boyle's method)	121
Table 3.4	Optical characteristics for cholesterol–ferric chloride-sulphuric acid complex in glacial acetic acid	122
Table 3.5	Calibration curve for methotrexate in methanol	123
Table 3.6	Optical characteristics for methotrexate in methanol	124
Table 3.7	Calibration curve for tamoxifen citrate in methanol	126
Table 3.8	Optical characteristics for tamoxifen citrate in methanol	126
Table 3.9	Calibration curve for cytarabine in methanol	129
Table 3.10	Optical characteristics for cytarabine in methanol	129
Table 3.11	Evaluation of accuracy and precision of the method for estimation of cytarabine in methanol	130
Table 3.12	Calibration curve for methotrexate in PBS	132
Table 3.13	Optical characteristics for methotrexate in PBS	132
Table 3.14	Calibration curve for tamoxifen citrate in PBS	135
Table 3.15	Optical characteristics for tamoxifen citrate in PBS	135
Table 3.16	Calibration curve for cytarabine in PBS	137
Table 3.17	Optical characteristics for cytarabine in PBS	137
Table 3.18	Evaluation of accuracy and precision of the method for estimation of cytarabine in PBS	138
Table 3.19	Calibration curve for mPEG5000-CC-PE	141
Table 3.20	Optical characteristics for mPEG5000-CC-PE	141
Table 3.21	Calibration curve for mPEG2000-CC-PE	142
Table 3.22	Optical characteristics for mPEG2000-CC-PE	142
Table 3.23	Calibration curve for mPEG5000-IC-PE	143
Table 3.24	Optical characteristics for mPEG5000-IC-PE	143

Table 4.1	Optimization of parameters for preparation of conventional liposomes containing methotrexate.	166
Table 4.2	Results of electrolyte induced flocculation test on conventional liposomes containing methotrexate	168
Table 4.3	Optimization of parameters for preparation of conventional liposomes containing tamoxifen citrate	170
Table 4.4	Results of electrolyte induced flocculation test on conventional liposomes containing tamoxifen citrate	172
Table 4.5	Optimization of preparation of conventional liposomes containing cytarabine	175
Table 4.6	Results of electrolyte induced flocculation test on conventional liposomes containing cytarabine	177
Table 4.7	Optimization of mPEG5000-CC-PE concentration, required for steric stabilization of methotrexate containing liposomes, using electrolyte induced flocculation test	190
Table 4.8	Optimization of mPEG5000-CC-PE concentration, required for steric stabilization of tamoxifen citrate containing liposomes, using electrolyte induced flocculation test	192
Table 4.9	Optimization of mPEG5000-CC-PE concentration, required for steric stabilization of cytarabine containing liposomes, using electrolyte induced flocculation test	194
Table 4.10	Optimization of mPEG2000-CC-PE concentration, required for steric stabilization of methotrexate containing liposomes, using electrolyte induced flocculation test	204
Table 4.11	Optimization of mPEG2000-CC-PE concentration, required for steric stabilization of tamoxifen citrate containing liposomes, using electrolyte induced flocculation test	206
Table 4.12	Optimization of mPEG2000-CC-PE concentration, required for steric stabilization of cytarabine containing liposomes, using electrolyte induced flocculation test	208
Table 4.13	Optimization of mPEG5000-IC-PE concentration, required for steric stabilization of methotrexate containing liposomes, using electrolyte induced flocculation test	217
Table 4.14	Optimization of mPEG5000-IC-PE concentration, required for steric stabilization of tamoxifen citrate containing liposomes, using electrolyte induced flocculation test	219
Table 4.15	Optimization of mPEG5000-IC-PE concentration, required for steric stabilization of cytarabine containing liposomes, using electrolyte induced flocculation test	221
Table 5.1	Attributes of plain and sterically stabilized liposomes containing MTX, TMX and CYT	242
Table 5.2	Analysis of variance (ANOVA) table for drug entrapment in conventional and sterically stabilized liposomes containing methotrexate	243
Table 5.3	Analysis of variance (ANOVA) table for drug entrapment in conventional and sterically stabilized liposomes containing tamoxifen citrate	243

Table 5.4	Analysis of variance (ANOVA) table for drug entrapment in conventional and sterically stabilized liposomes containing cytarabine	243
Table 6.1	*In vitro* drug release studies of conventional liposomes containing methotrexate	274
Table 6.2	*In vitro* drug release studies of liposomes containing methotrexate sterically stabilized with 5 mol% mPEG5000-CC-PE	275
Table 6.3	*In vitro* drug release studies of liposomes containing methotrexate sterically stabilized with 7 mol% PEG2000-CC-PE	275
Table 6.4	*In vitro* drug release studies of liposomes containing methotrexate sterically stabilized with 5 mol%mPEG5000-IC-PE	276
Table 6.5	*In vitro* drug release studies of conventional liposomes containing tamoxifen citrate	276
Table 6.6	*In vitro* drug release studies of liposomes containing tamoxifen citrate sterically stabilized with 5 mol% mPEG5000-CC-PE	277
Table 6.7	*In vitro* drug release studies of liposomes containing tamoxifen citrate sterically stabilized with 7 mol% mPEG2000-CC-PE	277
Table 6.8	*In vitro* drug release studies of liposomes containing tamoxifen citrate sterically stabilized with 5 mol% mPEG5000-IC-PE	278
Table 6.9	*In vitro* drug release studies of conventional liposomes containing cytarabine	278
Table 6.10	*In vitro* drug release studies of liposomes containing cytarabine sterically stabilized with 5 mol% mPEG5000-CC-PE	279
Table 6.11	*In vitro* drug release studies of liposomes containing cytarabine sterically stabilized with 7 mol% mPEG2000-CC-PE	279
Table 6.12	*In vitro* drug release studies of liposomes containing cytarabine sterically stabilized with 5 mol% mPEG5000-IC-PE	280
Table 6.13	Parameters of release kinetics for conventional and sterically stabilized liposomes containing methotrexate, tamoxifen citrate and cytarabine	280
Table 7.1	Particle size determination of the liposomal dispersions after storing at different temperatures for a period of 30 days	301
Table 7.2	Percentage drug retention of the liposomal dispersions after storing at different temperatures for a period of 30 days	302
Table 7.3	Steric stability studies of the liposomal dispersions after storing at different temperatures for a period of 30 days	303

Table 7.4	Particle size determination of the rehydrated lyophilized liposomal formulations after storing at different temperatures for a period of 6 months	305
Table 7.5	Percentage drug retention of the rehydrated lyophilized liposomal formulations after storing at different temperatures for a period of 6 months	306
Table 7.6	Steric stability studies of rehydrated lyophilized liposomal formulations after storing at different temperatures for a period of 6 months	307
Table 8.1	*In vitro* cytotoxicity study of methotrexate and its liposomes	319
Table 8.2	*In vitro* cytotoxicity study of tamoxifen citrate and its liposomes	320
Table 8.3	*In vitro* cytotoxicity study of cytarabine and its liposomes	322
Table 9.1	Effect of pH on radiolabeling efficiency of MTX and its liposomal formulations	333
Table 9.2	Effect of incubation time on radiolabeling efficiency of MTX and its liposomal formulations	335
Table 9.3	Effect of $SnCl_2.2H_2O$ concentration on radiolabeling efficiency of MTX and its liposomal formulations	336
Table 9.4	Stability studies of radiolabeled MTX and its liposomal formulations in saline	337
Table 9.5	Stability studies of radiolabeled MTX and its liposomal formulations in serum	337
Table 9.6	DTPA challenging test of MTX and its liposomal formulations	338
Table 9.7	Effect of pH on radiolabeling efficiency of TMX and its liposomal formulations	340
Table 9.8	Effect of incubation time on radiolabeling efficiency of TMX and its liposomal formulations	341
Table 9.9	Effect of $SnCl_2.2H_2O$ concentration on radiolabeling efficiency of TMX and its liposomal formulations	342
Table 9.10	Stability studies of radiolabeled TMX and its liposomal formulations in saline	343
Table 9.11	Stability studies of radiolabeled TMX and its liposomal formulations in serum	343
Table 9.12	DTPA challenging test of TMX and its liposomal formulations	344
Table 9.13	Effect of pH on radiolabeling efficiency of CYT and its liposomal formulations	346
Table 9.14	Effect of incubation time on radiolabeling efficiency of CYT and its liposomal formulations	347
Table 9.15	Effect of $SnCl_2.2H_2O$ concentration on radiolabeling efficiency of CYT and its liposomal formulations	348
Table 9.16	Stability studies of radiolabeled CYT and its liposomal formulations in saline	349

Table 9.17	Stability studies of radiolabeled CYT and its liposomal formulations in serum	349
Table 9.18	DTPA challenging test of CYT and its liposomal formulations	350
Table 10.1	Blood kinetic study of ^{99m}Tc labeled methotrexate (MTX)	362
Table 10.2	Blood kinetic study of ^{99m}Tc labeled conventional liposomes containing methotrexate (ML)	362
Table 10.3	Blood kinetic study of ^{99m}Tc labeled sterically stabilized liposomes containing methotrexate (SML5000-CC-PE)	363
Table 10.4	Blood kinetic study of ^{99m}Tc labeled sterically stabilized liposomes containing methotrexate (SML2000-CC-PE)	363
Table 10.5	Blood kinetic study of ^{99m}Tc labeled sterically stabilized liposomes containing methotrexate (SML5000-IC-PE)	364
Table 10.6	Blood kinetic study of ^{99m}Tc labeled tamoxifen citrate (TMX)	365
Table 10.7	Blood kinetic study of ^{99m}Tc labeled conventional liposomes containing tamoxifen citrate (TL)	365
Table 10.8	Blood kinetic study of ^{99m}Tc labeled sterically stabilized liposomes containing tamoxifen citrate (STL5000-CC-PE)	366
Table 10.9	Blood kinetic study of ^{99m}Tc labeled sterically stabilized liposomes containing tamoxifen citrate (STL2000-CC-PE)	366
Table 10.10	Blood kinetic study of ^{99m}Tc labeled sterically stabilized liposomes containing tamoxifen citrate (STL5000-IC-PE)	367
Table 10.11	Blood kinetic study of ^{99m}Tc labeled cytarabine (CYT)	368
Table 10.12	Blood kinetic study of ^{99m}Tc labeled conventional liposomes containing cytarabine (CL)	368
Table 10.13	Blood kinetic study of ^{99m}Tc labeled sterically stabilized liposomes containing cytarabine (SCL5000-CC-PE)	369
Table 10.14	Blood kinetic study of ^{99m}Tc labeled sterically stabilized liposomes containing cytarabine (SCL2000-CC-PE)	369
Table 10.15	Blood kinetic study of ^{99m}Tc labeled sterically stabilized liposomes containing cytarabine (SCL5000-IC-PE)	370
Table 10.16	Pharmacokinetic parameters for the *in vivo* studies of ^{99m}Tc labeled conventional and sterically stabilized liposomes containing methotrexate, tamoxifen citrate and cytarabine in rabbits	371
Table 10.17	Biodistribution of ^{99m}Tc - MTX in EAT bearing mice	372
Table 10.18	Biodistribution of ^{99m}Tc - ML in EAT bearing mice	372
Table 10.19	Biodistribution of ^{99m}Tc - SML5000-CC-PE in EAT bearing mice	373
Table 10.20	Biodistribution of ^{99m}Tc - SML2000-CC-PE in EAT bearing mice	373
Table 10.21	Biodistribution of ^{99m}Tc - SML5000-IC-PE in EAT bearing mice	374
Table 10.22	Biodistribution of ^{99m}Tc - TMX in EAT bearing mice	375

Table 10.23 Biodistribution of ^{99m}Tc - TL in EAT bearing mice 375
Table 10.24 Biodistribution of ^{99m}Tc - STL5000-CC-PE in EAT bearing mice 376
Table 10.25 Biodistribution of ^{99m}Tc - STL2000-CC-PE in EAT bearing mice 376
Table 10.26 Biodistribution of ^{99m}Tc - STL5000-IC-PE in EAT bearing mice 377
Table 10.27 Biodistribution of ^{99m}Tc - CYT in EAT bearing mice 378
Table 10.28 Biodistribution of ^{99m}Tc - CL in EAT bearing mice 378
Table 10.29 Biodistribution of ^{99m}Tc - SCL5000-CC-PE in EAT bearing mice 379
Table 10.30 Biodistribution of ^{99m}Tc - SCL2000-CC-PE in EAT bearing mice 379
Table 10.31 Biodistribution of ^{99m}Tc - SCL5000-IC-PE in EAT bearing mice 380
Table 10.32 Pharmacokinetic parameters for the *in vivo* studies of ^{99m}Tc labeled conventional and sterically stabilized liposomes containing methotrexate, tamoxifen citrate and cytarabine in mice 381
Table 10.33 *In vitro* testing for drug retention within liposomes containing methotrexate in human plasma 382
Table 10.34 *In vitro* testing for drug retention within liposomes containing tamoxifen citrate in human plasma 382
Table 10.35 *In vitro* testing for drug retention within liposomes containing cytarabine in human plasma 382
Table 11.1 Haematological parameters of mice after treatment with methotrexate and its liposomes 406
Table 11.2 Haematological parameters of mice after treatment with tamoxifen citrate and its liposomes 406
Table 11.3 Haematological parameters of mice after treatment with cytarabine and its liposomes 407